Economic evaluation of oral treatments for neuropathic pain.
The effectiveness of amitriptyline, carbamazepine, gabapentin, and tramadol for the treatment of neuropathic pain has been demonstrated, but it is unknown which one is the most cost-effective. We designed a cost-utility analysis of a hypothetical cohort with neuropathic pain of postherpetic or diabetic origin. The perspective of the economic evaluation was that of a third-party payor. For effectiveness and safety estimates, we performed a systematic review of the literature. For direct cost estimates, we used average wholesale prices, and the American Medicare and Clinical Laboratory Fee Schedules. For utilities of health states, we used the Health Utilities Index. We modeled 1 month of therapy. For comparisons among treatments, we estimated incremental cost per utility gained. To allow for uncertainty from variations in drug effectiveness, safety, and amount of medication needed, we conducted a probabilistic Monte Carlo simulation. Amitriptyline was the cheapest strategy, followed by carbamazepine, and both were equally beneficial. Gabapentin was the most expensive as well as the least beneficial. A multivariable probabilistic simulation produced similar results to the base-case scenario. In summary, amitriptyline and carbamazepine are more cost-effective than tramadol and gabapentin and should be considered as first-line treatment for neuropathic pain in patients free of renal or cardiovascular disease.


CONCLUSIONS
Prescription practices should be based on the best available evidence, which includes the evaluation of the medication's cost-effectiveness. This does not mean that the cheapest or the most expensive, but rather the most cost-effective medication should be chosen-the one whose benefits are worth the harms and costs. We report a cost-effectiveness evaluation of treatments for neuropathic pain.
Cepeda
M Soledad
MS
Department of Anesthesia and Clinical Epidemiology Unit, Javeriana University School of Medicine, Bogota, Colombia. scepeda@javeriana.edu.co
Farrar
John T
JT
D000284:Administration, Oral; D000588:Amines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D000639:Amitriptyline / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D003663:Decision Trees; D016527:Drug Costs; D000077206:Gabapentin; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy*; D014147:Tramadol / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*
D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D000639:Amitriptyline; D002220:Carbamazepine; D014147:Tramadol; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin